Vascular Contributions to Cognitive Impairment and Dementia

Topical Review of Animal Models

Jeremy B. Madigan, MD, FRCR; Donna M. Wilcock, PhD; Atticus H. Hainsworth, PhD

Cerebrovascular disease and Alzheimer disease (AD) lesions are common in older people and accumulate with age. Cerebrovascular lesions can directly reduce cognitive status: vascular dementia is the second most common cause of clinical dementia after AD. In addition, cerebrovascular lesions worsen the impact of AD and other dementia pathologies and may contribute to AD pathogenesis. This spectrum is reflected in the concept of vascular contributions to cognitive impairment and dementia (VCID).

There are numerous vascular pathologies underlying VCID. Parenchymal lesions associated with arteriolosclerosis, in small arteries (outer diameter up to \( \approx 200 \) µm) that supply deep nuclei and deep white matter areas in the human brain, are small focal infarcts (lacunes), diffuse white matter lesions (WML), and microhemorrhages. Other VCID-related vascular pathologies include microatheroma, venous collagenses, and cerebral amyloid angiopathy.

The limitations of animal models for VCID are well-known. Experimental species differ from humans in terms of lifespan, relative white matter abundance, large artery dimensions (Figure 1), and in size and morphology of deep penetrating arteries (Figure 2). Nevertheless, animal paradigms provide valuable insights into mechanisms, progression, and possible therapies in VCID. All experimental use of animals for human health-related research carries ethical responsibilities and must be governed by internationally-agreed Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines. Here, we update a previous systematic review of VCID-relevant models (online-only Data Supplement) and summarize instructive examples (Table).

**Hyopperfusion: Rats and Mice**

Bilateral surgical ligation of the common carotid arteries (2-vessel occlusion) in rats remains the most frequently used model. Bilateral carotid artery stenosis (BCAS) in mice, using metal coils to narrow the arteries by 50%, produces a less-severe, chronic global hypoperfusion. BCAS mice develop some white matter damage and increased blood–brain barrier (BBB) permeability and cognitive impairment. Fludeoxyglucose (F-18) positron emission tomography indicates a decrease in hippocampal glucose utilization 6 months post BCAS. In the radial maze and Barnes maze tasks, working memory was impaired at 30 days. Impaired reference memory was also detected at 5 to 6 months post surgery.

After 6 months of stenosis, the animals display significantly (30%) reduced fractional anisotropy on diffusion tensor imaging in white matter areas. Histologically, they exhibit thickened basement membrane collagen IV (relative to 1 month post BCAS and sham-operated animals) and hippocampal atrophy with pyknotic and apoptotic cells from 6 to 8 months post surgery. An unexpected finding in BCAS mice is the incidence at 6 months of subcortical hemorrhagic lesions, detected on magnetic resonance imaging (MRI) and confirmed histologically. The hemorrhagic lesions, and an astrogliosis response with unusual distribution of aquaporin-4, suggest a pathological process additional to global hypoperfusion.

To produce more gradual cerebral blood flow (CBF) reduction, amieor microconstrictor cuffs filled with casein (which swells on absorbing water) are placed around the carotid arteries of rats. In rats gradual bilateral occlusion (2-vessel gradual occlusion) over 2 to 3 days leads to comparable CBF reduction and white matter damage, with lower mortality and hippocampal neuronal death, relative to the standard 2-vessel occlusion rat model. 2-vessel gradual occlusion in hypertensive (SHR) rats produced a gradual reduction in global CBF (to 68% of baseline values, after 7 days) and cognitive impairment in the Y-maze. Mice with an amieor constrictor placed on 1 common carotid artery and a microcoil causing 50% stenosis on the other (so-called amieor constrictor, arterial stenosis, or ACAS mice) exhibit subcortical infarcts in addition to diffuse

---

Received March 7, 2016; final revision received May 10, 2016; accepted May 19, 2016.

From the Cardiovascular and Cell Sciences Research Institute, St George’s University of London, London, United Kingdom (J.B.M., A.H.H.); Neuroradiology Department, St George’s Hospital, London, United Kingdom (J.B.M.); Atkinson Morley Neurosciences, St George’s University Hospitals NHS Foundation Trust, London, United Kingdom (J.B.M., A.H.H.); and Sanders-Brown Center on Aging, University of Kentucky, Lexington (D.M.W.).

The online-only Data Supplement is available with this article at http://stroke.ahajournals.org/lookup/suppl/doi:10.1161/STROKEAHA.116.012066/-/DC1.

Correspondence to Atticus H. Hainsworth, PhD, St George’s University of London, Mailpoint J-0B, Cranmer Terrace, London SW17 0RE, United Kingdom. E-mail ahainsworth@sgul.ac.uk

(Stroke. 2016;47:1953-1959. DOI: 10.1161/STROKEAHA.116.012066.)

© 2016 American Heart Association, Inc.

Stroke is available at http://stroke.ahajournals.org

DOI: 10.1161/STROKEAHA.116.012066

1953
white matter damage. ACAS mice exhibited gradual reduction of CBF ≥28 days, and multiple infarct damage in subcortical regions ipsilateral to the amnoid constrictor cuff, observed in 81% of the mice. At day 28 post surgery, ACAS mice showed significant decrease in spatial working memory.11

Hypoperfusion: Baboons
In adult baboons (Papio anubis; age ≥12 years) occluding 1 vertebral and both internal carotid arteries (termed 3-vessel occlusion), led to a severe hypoperfusion state. Activation of microglia was marked at 3 days post occlusion, and plasma extravasation at 7 to 14 days, both being resolved by 28 days. From 7 days post occlusion, these animals developed progressive white matter pallor and vacuolation in the corpus callosum, deep subcortical and periventricular white matter areas, with some demyelination, up to 28 days. Although a primate surgical model poses substantial logistic challenges, data from a human-like experimental species with extensive white matter are uniquely valuable. For VCID-relevant research, it is notable that aging baboons exhibit both β-amyloid and tau neuropathology.

Hypoperfusion Paradigms in Relation to Clinical SVD and VCID
Regional CBF in white matter is universally low across species (Figure 1). This is generally considered to explain the white matter predilection for diffuse hypoperfusion lesions. In human brain, the deep subcortical white matter is supplied by the distal fields of deep penetrating medullary arteries (length ≥50 mm) arising from the leptomeningeal branches of the anterior, middle, and posterior cerebral arteries. Thus, even under normal circumstances, this deep white matter is subject to relatively low perfusion pressure. Although there are some anastomoses between these vessels, an episode of profound global hypoperfusion (eg, acute internal carotid artery occlusion) causes white matter infarcts in a characteristic deep or internal borderzone distribution. Experimental induction of abnormally low perfusion pressure in an animal (eg, 2-vessel occlusion or 3-vessel occlusion models) would be expected to cause ischemic white matter damage with a similar pattern.

A caveat is that pathogenesis of WML in these hypoperfusion models is different from human SVD. The majority of WML and lacunes in humans are thought to arise as a direct result of local small vessel wall changes not of embolic events or episodes of global hypoperfusion. Hence, although experimental proximal large vessel occlusion will cause white matter changes, the distribution of lesions is likely to be more confined and stereotyped, and other features contributing to the local milieu in chronic hypertensive arteriopathy, such as BBB dysfunction are likely to be different in such models, or absent. Furthermore, any vascular adaptions such as ischemic preconditioning are unlikely, except where occlusion is more gradual (eg, 2-vessel gradual occlusion).

Hypertensive Rodents With Comorbidities
Spontaneously hypertensive stroke prone rats (SHRSP) develop severe hypertension from 9 to 12 weeks of age and typically exhibit stroke lesions at 9 to 12 months, with 90% mortality by 12 months of age. Stroke lesions are frequently hemorrhagic in nature and are unpredictable in timing, severity, location, and behavioral outcome. In the absence of comorbidities, stroke-free SHRSP exhibit little white matter change on MRI or histologically. In SHRSP subjected to unilateral carotid artery occlusion, then a combination of low-protein, high salt diet (so-called Japanese permissive diet), and NaCl (1%wt/vol)—supplemented drinking water, diffuse WML were seen on MRI. These were accompanied by impaired performance in the Morris water maze. Histologically there was loss of myelin, signs of inflammatory response, and matrix metalloproteinase (MMP)–mediated BBB disruption. Although mature oligodendrocytes were depleted in white matter of SHRSP, oligodendrocyte progenitor cells paradoxically increased in density. The WML were accompanied by hypoperfusion, determined by arterial spin labeling labeling MRI, and reduced brain tissue pO2 measured by electron paramagnetic resonance. Hypoxia-inducible factor-1α, activating MMP2, may be the pathway for BBB disruption. The antibiotic minocycline has both anti-inflammatory and antiapoptotic activity. Young SHRSP were treated with this drug (50 mg/kg IP, every 2 days) for 9 weeks, after the unilateral carotid artery occlusion surgery and transfer to Japanese permissive diet. Minocycline-treated animals showed an impressive protection from WML on MRI, modest improvement in the Morris water maze, and increased lifespan, relative to vehicle-treated animals.

Figure 1. Lifespan and cerebral large artery diameter, white matter content and blood flow: comparison across species. A. Normal lifespan (open circles) and outer diameter (OD) of the middle cerebral artery (MCA; μm). Typical data for mouse (Ms), rat, cat, dog, monkey (Macaque), and human. B. White matter volume as a fraction (% WMF) of total cerebral volume (squares), global cerebral blood flow (CBF, ◦), and white matter CBF (WM; ○). X-axis shows greatest whole brain width in coronal section (mm).
Although SHRSP develop severe hypertension, milder chronic hypertension is induced by supplementing drinking water with the NOS-inhibitor L-N-Nitroarginine methyl ester, or chronic infusion of angiotensin II by minipump. Mice receiving a subpressor infusion of angiotensin II develop mild hypertension (mean arterial blood pressure 90 mm Hg, relative to 70 mm Hg in saline-infused controls). In addition to vascular actions, subpressor concentrations of the hypertensive agent may have direct effects on neural organization and metabolism.

Hyperhomocysteinemia in Mice and Rats
Elevated plasma concentration of the nonessential amino acid homocysteine, termed hyperhomocysteinemia, is a risk factor for VCID. In wild-type mice, a diet deficient in 3 B vitamins (B6, B9-folate, and B12) resulted in hyperhomocysteinemia within 10 weeks, accompanied by reduced capillary density in brain tissue and impaired performance in Morris water maze. The same dietary regime also exacerbated cognitive impairment in amyloid precursor protein (APP) transgenic mice. Maintaining wild-type mice for 12 weeks on a diet enriched for the homocysteinemia precursor methionine, in addition to B6/B9/B12 deficiency, resulted in plasma (homocysteine) in the range of 70 to 90 µmol/L, classified as moderate hyperhomocysteinemia in mice (physiological range for plasma [homocysteine] in healthy mice and humans, 5–10 µmol/L). These mice exhibited cognitive impairment on the 2-day radial arm water maze, increased metalloproteinase (MMP2, MMP9) activity in brain tissue, and small focal cerebral hemorrhages. In rats, B9-folate deficiency alone was sufficient to induce hyperhomocysteinemia and cognitive impairment and to exacerbate pathology associated with other models of VCID.

Table. Overview of Selected Models Relevant to VCID

<table>
<thead>
<tr>
<th>Model</th>
<th>Cognitive Impairment</th>
<th>Brain Pathology</th>
<th>Selected References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global hypoperfusion: rat 2VO, 2VGO; mouse BCAS, ACAS</td>
<td>Working memory deficits; later, RM deficits (MWM, Barnes maze, Y-maze)</td>
<td>Diffuse WML; some BBB deficit, microglial activation; microhemorrhages at 6 mo</td>
<td>9–12</td>
</tr>
<tr>
<td>Global hypoperfusion: baboon 3VO</td>
<td>Not reported</td>
<td>Progressive, diffuse WML; transient microglial activation; transient global BBB opening</td>
<td>13</td>
</tr>
<tr>
<td>SHRSP, with JPD and UCCAo</td>
<td>Memory deficits (MWM)</td>
<td>Diffuse WML; neuroinflammation, BBB deficit</td>
<td>14–16</td>
</tr>
<tr>
<td>HHCy in mice, rats</td>
<td>Learning deficits (MWM)</td>
<td>Micro-hemorrhages; CAA</td>
<td>17–20</td>
</tr>
<tr>
<td>Notch3 transgenic mice</td>
<td>Not reported</td>
<td>Vessel fibrosis; later, WML; reduced CBF. No BBB deficit</td>
<td>21–24</td>
</tr>
<tr>
<td>ApoE-deficient mice</td>
<td>Learning deficits (MWM, Barnes maze)</td>
<td>BBB deficit (from 2 wk); CAA</td>
<td>25–28</td>
</tr>
</tbody>
</table>

2VO indicates 2-vessel gradual occlusion; 2VO, 2-vessel occlusion; 3VO, 3-vessel occlusion; ACAS, ameroid constrictor, arterial stenosis; BBB, blood–brain barrier; BCAS, bilateral carotid artery stenosis; CAA, cerebral amyloid angiopathy; CBF, cerebral blood flow; HHCy, hyperhomocysteinemia; JPD, Japanese permissive diet; MWM, Morris water maze; RM, reference memory; SHRSP, spontaneously hypertensive stroke prone rats; UCCAo, unilateral common carotid artery occlusion; VCID, vascular contributions to cognitive impairment and dementia; and WML, white matter lesions.
reduce cerebral blood volume and reactivity measured by absolute, noninvasive, near-infrared spectroscopy. Although the molecular mechanism of hyperhomocysteinemia-induced VCID is unclear, the locus of pathology seems to be vascular, rather than neuronal.

**Animal Models of BBB Dysfunction**

*Pdgfrα−/−* mice deficient in pericytes, the contractile cells that ensheathe capillary vessels, showed progressive BBB breakdown from 1 month of age, with increasing extravasation of plasma proteins in the hippocampus and cerebral cortex. This was accompanied by reduced capillary density and age-dependent reduction in baseline CBF and response to a vasogenic stimulus (whisker twitch). By 16 months of age, the mice exhibited pronounced neuronal loss within the hippocampus, accompanied by impaired performance in a simple assay of learning (novel object recognition task).

APOE genotype is a risk factor for sporadic AD. The APOE ε4 allele increases risk, possibly via a toxic effect of the APOE ε4 gene product, or via loss of physiological APOE function. In an elegant series of target replacement (TR) studies, mice lacking native ApoE expressed the human alleles APOE 2, 3, or 4, under an astrocyte-specific promoter. TR mice carrying only the APOE ε4 allele (like ApoEε−/− null mice) exhibited enhanced BBB permeability that was evident by 2 weeks of postnatal age. This was dependent on MMP9 activity, induced via the proinflammatory cytokine cyclophilin-A. None of these changes was evident in APOEε2 or APOEε3 TR mice. APOE4 TR mice exhibited worse spatial memory relative to age-matched APOEε3 TR animals not only at older ages (12 and 24 months) but also in young adulthood (3 months).

Regional CBF was much reduced in the APOE4 TR or ApoEε−/− null animals at 9 months of age. CBF could be restored and was at normal levels in double knockout animals, lacking ApoE and the gene for cyclophilin-A. These well-defined transgenic animal systems allow specific biochemical pathways to be explored. The gene product of APOE3 binds to the membrane transporter LR1, and this suppresses the harmful effects of cyclophilin-A on MMP9 activation and BBB breach. These experiments also suggest that the harmful effect of APOE4 is loss of function, rather than a toxic action of the APOE4 gene product. A functional APOE and LR1 transport system stimulates clearance of amyloid peptides and possibly other brain parenchymal debris. Furthermore, when APOE4 TR mice are crossed to the APP transgenic mouse models of amyloid deposition, cerebral amyloid angiopathy is significantly increased, suggesting a potential role for ApoE4 in the vascular accumulation of amyloid.

Another molecular participant in β-amyloid clearance from brain tissue is PICALM, a phosphoinositide-binding protein associated with clathrin that is required for endocytosis and internalization of cell surface receptors. PICALM interacts with endothelial LR1 to mediate β-amyloid clearance from brain tissue. Heterozygous Picalmε+/− mice, expressing subphysiological levels of PICALM protein in brain endothelium, exhibited increased β-amyloid neuropathology and some cognitive impairment and assessed with measures of nest-building and burrowing. PICALM has emerged as a candidate in genome-wide association studies for AD, suggesting a key role in the pathogenesis of AD and dementia.

**CADASIL and CARASIL Mice**

CADASIL (Cerebral Autosomal Dominant Arteriopathy With Sub-Cortical Infarcts and Leukoencephalopathy) and CARASIL (Cerebral Autosomal Recessive Arteriopathy With Sub-Cortical Infarcts and Leukoencephalopathy) are rare monogenic forms of SVD, leading to early onset VCID. In CADASIL, the underlying gene is NOTCH3; in CARASIL, the gene is HTRA1.

Notch3R169C transgenic mice have 4-fold overexpression of CADASIL-associated mutant Notch3. These mice exhibit detective CBF reactivity from 5 months of age, reduced CBF from 12 months, and progressive WML from 18 months. The main WML were microvacuoles within the myelin sheath, suggested to reflect defective ion-water homeostasis. There was no apparent loss of oligodendrocyte density, and axons were intact. The extracellular matrix proteins vitronectin and tissue inhibitor of metalloproteinases-3 (TIMP-3) accumulated in the vascular granular osmiophilic material deposits that are characteristic of CADASIL. Double-transgenic mice that express CADASIL-causing Notch3 mutations, in addition to being heterozygous null for vitronectin, exhibit rescue from WML at 12 to 20 months of age, but not rescue of impaired CBF. Stroke lesions have not been reported for these mice (up to age 24 months). Another transgenic strain has recently been reported, carrying the human genomic NOTCH3 sequence. Knockin Notch3Arg170Cys mouse models, with a mutation in the endogenous Notch3 gene, developed a CADASIL-like vessel pathology and, in addition, some incidence of parenchymal lesions (from 20 months of age). Microinfarcts, microhemorrhages, and behavioral motor deficits were seen in a minority (up to 12%) of these mutant mice up to the age of 13 months.

HTRA1 encodes a secreted serine protease that is involved in transforming growth factor-β signaling. CARASIL-causing mutations result in loss of Htra1 activity. Brain tissue from Htra1ε−/− null mice, and fibroblasts from CARASIL patients, exhibited reduced transforming growth factor-β signaling and dysregulation of an extracellular transforming growth factor-β-binding protein that is a novel Htra1 target. In brain tissue from Htra1 null mice, LTBP1 levels were augmented and transforming growth factor-β signaling was depressed.

**Discussion**

**Comorbid Models**

Greater understanding of interactions between risk factors, genotype, and specific vascular lesions (Figure 3) may come from animals with multiple pathologies and comorbidities. Examples are hypertensive rats with Japanese permissive diet and brain hypoperfusion or diet-induced hyperhomocysteinemia combined with AD pathology. Molecular understanding is more advanced in AD than in VCID, and transgenic AD models are well established. VCID–AD overlap and interaction may therefore be explored using vascular challenges combined with brain-injected Aβ peptides or in APP transgenic animals.
Larger Species
Larger animals (primates, dogs, sheep, and swine) have longer natural life span than rodents and offer valuable data relevant to the human brain gyrencephalic anatomy, abundant white matter, and arterial morphology (Figure 2), even though cohort sizes may necessarily be limited. They can be subjected to VCID-relevant risk factors (old age, hypertension, high-fat diet, and physical exercise status). Rhesus macaques 20 to 30 years of age are considered analogous to older people 60 to 90 years of age. Quantitative MRI of these animals shows a highly significant reduction in white matter volume with increasing age. In old dogs, a cognitive dysfunction syndrome, featuring some aspects of VCID, has been described. Experimental sheep models have recently been developed to simulate acute ischemic stroke. Sophisticated cognitive testing paradigms are available for primates. By contrast, cognitive paradigms for large domestic species are currently rudimentary.

Small Species: Zebrafish
Perturbation of FOXC1 (which encodes a forkhead-like transcription factor) in Danio rerio led to cerebral hemorrhages. Genome-wide association studies suggested possible link-age of the FOXC1 locus with SVD phenotype (white matter hyperintensities). Suppression of FOXC1 also affected platelet-derived growth factor (PDGF) signaling and central nervous system development. The zebrafish offers a rapid screening platform for genetic alterations.

Summary
Animal models have great potential to increase our understanding of specific vessel pathologies, how these cause parenchymal lesions, how known risk factors influence vessel and parenchymal changes, and the mechanisms that link them all to VCID (Figure 3).

For example, transgenic animals permit well-controlled testing of molecular hypotheses on a functional pathway, such as ApoE-mediated clearance. CADASIL mice carrying Notch3 mutations combine a known molecular cause with biologically appropriate vessel pathology and parenchymal lesions reminiscent of human SVD. The risk factor hyperhomocysteinemia is induced by dietary manipulation in rodents, which exhibit vessel fibrosis, microhemorrhages, and cognitive deficits. Hyperhomocysteinemia mice and rats offer a valuable platform for identifying the currently unknown molecular targets of hyperhomocysteinemia-related brain disease. Diffuse WML can be induced in rodents after chronic hypoperfusion and also in SHRSP with dietary and surgical comorbidities, in both conditions with some concomitant cognitive deficit. As noted, the vascular pathology in these animals is likely to differ from human VCID (Figure 3).

There are several directions for future progress. In our view, experimental species with closer metabolic and immunologic similarity to humans (primates and larger domestic species) will make preclinical testing of interventions more translational. Given the multifactorial nature of the VCID spectrum, comorbid animals may also accelerate discovery biology for VCID treatments. Although the models discussed here clearly do not reflect the full pathogenic pathway of human disease (Figure 3), they represent a pragmatic test-bed for interventions. VCID is a broad concept, and there is no one optimal VCID model. We hope that this review will assist...
Sources of Funding

We gratefully acknowledge funding from Alzheimer Drug Discovery Foundation (ADDF grant no. 20140901), Alzheimers Society UK (PG14/151) and Alzheimeas Research UK (PPG2014A-8) to Dr Hainsworth and Dr Madigan, and from the National Institute of Neurological Disorders and Stroke/National Institutes of Health (grant R01NS079637) to Dr Wilcock.

Disclosures

None.

References


**Key Words:** Alzheimer disease ■ cerebral small vessel disease ■ cerebrovascular circulation ■ hyperhomocysteinemia ■ vascular dementia
Vascular Contributions to Cognitive Impairment and Dementia: Topical Review of Animal Models
Jeremy B. Madigan, Donna M. Wilcock and Atticus H. Hainsworth

Stroke. 2016;47:1953-1959; originally published online June 14, 2016; doi: 10.1161/STROKEAHA.116.012066

Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2016 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/47/7/1953

Data Supplement (unedited) at:
http://stroke.ahajournals.org/content/suppl/2016/06/27/STROKEAHA.116.012066.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org/subscriptions/
SUPPLEMENTAL MATERIAL

Vascular contributions to cognitive impairment and dementia (VCID): Topical Review of Animal Models

Jeremy B Madigan\textsuperscript{1,2,3} MD, FRCR, Donna M Wilcock\textsuperscript{4} PhD, Atticus H Hainsworth\textsuperscript{1,3} PhD

\textsuperscript{1}Cardiovascular and Cell Sciences Research Institute, St Georges University of London, London SW17 0RE, UK.
\textsuperscript{2}Neuroradiology Department, St George’s Hospital, Blackshaw Road, London, UK
\textsuperscript{3}Atkinson Morley Neurosciences, St George’s University Hospitals NHS Foundation Trust, London SW17 0QT, UK
\textsuperscript{4}Sanders-Brown Center on Aging, University of Kentucky, Lexington KY 40536, USA.

Correspondence: Dr AH Hainsworth, St George’s University of London, Cranmer Terrace, London SW17 0RE, United Kingdom. tel +44 208 725 5586 fax +44 208 725 2950 e-mail ahainsworth@sgul.ac.uk
Supplementary Method

Search Strategy for systematic review. Using PubMed, we searched English language publications in the period 01/01/2010–31/01/2016 for the following terms: (brain OR cerebral) AND (cogniti* OR dement*) AND (Vascular OR cerebrovascular OR arteri*) AND (vivo OR rodent OR rat OR mouse OR murine OR rabbit OR gerbil OR hamster OR porcine OR swine OR cat OR feline OR dog OR canine OR primate OR monkey OR marmoset OR baboon).

This search yielded 238 hits, of which 33 were reviews. For the remaining 205 papers, abstracts were independently screened by two authors (JBM, AHH) and the following exclusion criteria applied: not an animal model; not an in vivo model; not an appropriate disease/injury model; review article, without original data; conference abstract or other non-peer-reviewed source. Conflicts (on 25 selections) were resolved by discussion. Additional hits were added from bibliographies of included papers, and review articles. A final list of 100 papers were selected (below). Compare with our previous systematic review1.

Supplementary Results

Models retrieved by systematic review 2010-2016

Chronic hypoperfusion

Rat; bilateral common carotid artery occlusion (BCCAo); also referred to as two-vessel occlusion (2-VO)2-38

Rat; two vessel gradual occlusion (2-VGO)39; 2-VGO in SHR rats40

Rat; three vessel occlusion (3-VO)41

Mice; bilateral carotid artery stenosis (BCAS)42-48; BCAS in ASK−/− mice49; BCAS in mice with HHCy50

Mice; unilateral common carotid artery occlusion (UCCAo)51, 52; UCCAo with intra-gastric C. butyricum53

Baboons; 3-VO, 28 days54

Acute global ischaemia

Mice; transient BCCAo55

Hyperhomocysteinemia (HHCy)

Rats; dietary induction of HHCy56-59; high homocysteine and/or high cholesterol diet60

Mice; dietary induction of HHCy61, 62

Cystathionine beta-synthase deficient (CBS−/−) mice 63, 64
Diabetes mellitus-related changes and insulin/glucose control

Diabetic rats; streptazocin-treated\textsuperscript{65}

Diabetic rats; obese-Zucker\textsuperscript{66}; Otsuka Long-Evans Tokushima Fatty rats, with 2-VO\textsuperscript{67}

Mice with CNS-restricted deletion of the insulin receptor substrate protein 2 (IRS-2)\textsuperscript{68}

Hypertensive animals

Hypertensive rats (renal artery ligation)\textsuperscript{69}

Hypertensive rats SHRSP\textsuperscript{70-72}

Hypertensive rats SHR\textsuperscript{73}

Hypertensive mice; NADPH oxidase subunit Nox2-deficient; aortic banding; dietary L-NAME\textsuperscript{74}

Hypertensive mice; chronic administration of angiotensin II\textsuperscript{75}

Endothelial NO synthase deficient, eNOS\textsuperscript{+/-} mice\textsuperscript{76}

With focal ischaemic lesions

Middle cerebral artery occlusion (MCAo), P2Y\textsubscript{1}-null mice\textsuperscript{77}

Mice; permanent single penetrating arteriole occlusion\textsuperscript{78, 79}

Rats; micro-particle emboli (50-180 µm)\textsuperscript{80}

Mice; multiple micro-infarcts induced by injection of cholesterol emboli (40-70 µm), in addition to unilateral internal carotid artery occlusion\textsuperscript{81}

Vascular features of AD-relevant models

APP/PS1 transgenic mice; CAA, micro-hemorrhage\textsuperscript{82}

APP transgenic mice (Tg2576 strain); with UCC Ao\textsuperscript{83}

Rat; intra-striatal injections of endothelin-1 (ET1) and β-amyloid\textsuperscript{84}

Rat; β-amyloid i.c.v. injections in addition to 2-VO\textsuperscript{85}

Tau transgenic mice (rTg4510 strain); vascular effects\textsuperscript{86, 87}

Mice; Apoe-deficient, APOE2/APOE3/APOE4-expressing; CypA-deficient\textsuperscript{88}

CADASIL and CARASIL-related mice

Cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) Notch3 transgenic mice\textsuperscript{89-92}

CADASIL Notch3 transgenic mice; with MCAo\textsuperscript{93}
Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) HtrA1 null mice94

Miscellaneous
Rats; alpha-adrenoceptor autoantibodies95
Senescence-accelerated mouse prone 8 (SAMP8) mice96
Rats; involuntary physical exercise97
Rats; long term (12 month) dietary ethanol and/or high dietary cholesterol56, 98
Mice; hippocampal C-reactive protein (CRP) injection99
Rats; vascular calcification (0.75% adenine)100
Mice; Endothelia-specific depletion of the transcription factor Serum Response Factor SRF101

Supplementary References


(7) Li WX, Deng YY, Li F, Liu B, Liu HY, Shi JS et al. Icariin, a major constituent of flavonoids from Epimedium brevicornum, protects against cognitive deficits


(9) Ozacmak VH, Sayan-Ozacmak H, Barut F. Chronic treatment with resveratrol, a natural polyphenol found in grapes, alleviates oxidative stress and apoptotic cell death in ovariectomized female rats subjected to chronic cerebral hypoperfusion. Nutr Neurosci. 2015.


(38) Yao Y, Han DD, Zhang T, Yang Z. Quercetin improves cognitive deficits in rats with chronic cerebral ischemia and inhibits voltage-dependent sodium channels in hippocampal CA1 pyramidal neurons. Phytother Res. 2010;24:136-140.


(64) Beard RS, Jr., Reynolds JJ, Bearden SE. Hyperhomocysteinemia increases permeability of the blood-brain barrier by NMDA receptor-dependent regulation of adherens and tight junctions. Blood. 2011;118:2007-2014.


